Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • Triple negative • Ohio State University • NCI-CCC Breast Tumor Board Question
After WBRT, what systemic therapy would you favor for maximal CNS penetrance in a patient with triple negative metastatic breast cancer and multifocal CNS disease?
Is there any evidence for sacituzumab govitecan (IMMU-132) in this situation with progressive systemic disease after prior anthracycline and taxane?
Answer from: Medical Oncologist at Academic Institution
With patients such as this, I would usually recommend the following:
1. Genomic testing (Strata, Foundation 1, etc.) to look for a mutation that might be targetable with a TKI that crosses the blood brain barrier well
2. Re-testing of the CNS cytology for HER2, given that we do have multiple drugs...
Sign in or Register to read more